Total Payments
$59,255
2024 Payments
$10,383
Companies
33
Transactions
132
Medicare Patients
1,013
Medicare Billing
$182,754
Payment Breakdown by Category
Consulting$46,281 (78.1%)
Travel$5,261 (8.9%)
Other$4,032 (6.8%)
Food & Beverage$3,330 (5.6%)
Research$178.58 (0.3%)
Education$172.68 (0.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $46,281 | 16 | 78.1% |
| Travel and Lodging | $5,261 | 14 | 8.9% |
| Food and Beverage | $3,330 | 87 | 5.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,532 | 3 | 4.3% |
| Honoraria | $1,500 | 1 | 2.5% |
| Unspecified | $178.58 | 1 | 0.3% |
| Education | $172.68 | 10 | 0.3% |
Payments by Type
General
$59,076
131 transactions
Research
$178.58
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Fujirebio Diagnostics, Incorporated | $14,608 | 1 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $9,811 | 17 | $0 (2024) |
| Genentech USA, Inc. | $8,204 | 11 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $7,901 | 7 | $0 (2018) |
| Genentech, Inc. | $4,707 | 12 | $0 (2022) |
| AstraZeneca UK Limited | $3,532 | 4 | $0 (2024) |
| Aadi Bioscience, Inc. | $2,000 | 3 | $0 (2024) |
| F. Hoffmann-La Roche AG | $1,654 | 3 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,500 | 1 | $0 (2023) |
| G1 Therapeutics, Inc. | $1,500 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,383 | 24 | Genentech USA, Inc. ($4,364) |
| 2023 | $7,336 | 13 | Genentech USA, Inc. ($3,667) |
| 2022 | $2,212 | 17 | G1 Therapeutics, Inc. ($1,500) |
| 2021 | $10.87 | 1 | Merck Sharp & Dohme Corporation ($10.87) |
| 2020 | $17,020 | 12 | Fujirebio Diagnostics, Incorporated ($14,608) |
| 2019 | $2,612 | 15 | F. Hoffmann-La Roche AG ($1,476) |
| 2018 | $11,478 | 22 | Takeda Pharmaceuticals U.S.A., Inc. ($7,901) |
| 2017 | $8,202 | 28 | AstraZeneca Pharmaceuticals LP ($7,703) |
All Payment Transactions
132 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $24.10 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Consulting Fee | Cash or cash equivalent | $3,915.00 | General |
| Category: BioOncology | ||||||
| 11/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Travel and Lodging | Cash or cash equivalent | $309.00 | General |
| Category: BioOncology | ||||||
| 11/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | In-kind items and services | $82.97 | General |
| Category: BioOncology | ||||||
| 11/03/2024 | Genentech USA, Inc. | Alecensa (Biological), Tecentriq | Food and Beverage | Cash or cash equivalent | $10.94 | General |
| Category: BioOncology | ||||||
| 10/20/2024 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $46.38 | General |
| Category: Oncology | ||||||
| 09/10/2024 | Coherus Biosciences Inc. | — | Food and Beverage | In-kind items and services | $46.00 | General |
| 09/04/2024 | Aadi Bioscience, Inc. | Fyarro (Drug) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Cancer | ||||||
| 09/03/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $23.80 | General |
| Category: ONCOLOGY | ||||||
| 08/31/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $22.04 | General |
| Category: ONCOLOGY | ||||||
| 08/25/2024 | Aadi Bioscience, Inc. | — | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| 08/22/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $65.23 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 07/25/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 06/26/2024 | Olympus America Inc. | SPiN Vision Video Processor (Device) | Food and Beverage | In-kind items and services | $20.42 | General |
| Category: Respiratory | ||||||
| 06/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| 06/04/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $32.66 | General |
| 06/02/2024 | Genentech USA, Inc. | — | Food and Beverage | In-kind items and services | $46.49 | General |
| 06/01/2024 | Coherus Biosciences Inc. | Udenyca (Biological) | Food and Beverage | In-kind items and services | $142.27 | General |
| Category: Granulocyte colony stimulating factor | ||||||
| 02/22/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $19.31 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 02/19/2024 | AstraZeneca UK Limited | — | Travel and Lodging | Cash or cash equivalent | $1,290.44 | General |
| 02/19/2024 | AstraZeneca UK Limited | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,056.09 | General |
| 02/19/2024 | AstraZeneca UK Limited | — | Travel and Lodging | Cash or cash equivalent | $1,011.67 | General |
| 02/19/2024 | AstraZeneca UK Limited | — | Travel and Lodging | Cash or cash equivalent | $174.28 | General |
| 02/06/2024 | Novartis Pharmaceuticals Corporation | Fabhalta (Drug) | Food and Beverage | In-kind items and services | $20.05 | General |
| Category: Immunology | ||||||
| 11/30/2023 | Aadi Bioscience, Inc. | Fyarro (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Cancer | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK123, ROS1, or ALK Gene Rearrangements, A Phase I Dose Escalation Study of Entrectinib RXDX-101 in Adult patients with AdvancedMetastatic Solid Tumors, A Phase 1, Multicenter, Open-Label Study of Oral Entrectinib RXDX-101 in Adult Patients with Locally Advanced or Metastatic Cancer Confirmed to be Positive for NTRK1, NTRK2 | F. Hoffmann-La Roche AG | $178.58 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 253 | 523 | $199,865 | $40,945 |
| 2022 | 7 | 267 | 649 | $232,235 | $47,394 |
| 2021 | 7 | 284 | 781 | $272,795 | $56,462 |
| 2020 | 5 | 209 | 589 | $220,375 | $37,952 |
Total Patients
1,013
Total Services
2,542
Medicare Billing
$182,754
Procedure Codes
26
All Medicare Procedures & Services
26 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 93 | 295 | $118,000 | $23,126 | 19.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 64 | 120 | $33,000 | $6,277 | 19.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 27 | 31 | $16,585 | $3,775 | 22.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 24 | 24 | $18,000 | $3,354 | 18.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $7,990 | $2,082 | 26.1% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 12 | 19 | $3,230 | $1,275 | 39.5% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2023 | 16 | 17 | $3,060 | $1,056 | 34.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 94 | 370 | $148,000 | $29,732 | 20.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 86 | 170 | $46,750 | $8,919 | 19.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 18 | 18 | $13,500 | $2,702 | 20.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 20 | 23 | $12,305 | $2,659 | 21.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 24 | 39 | $6,630 | $2,342 | 35.3% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2022 | 12 | 12 | $2,160 | $693.54 | 32.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2022 | 13 | 17 | $2,890 | $345.53 | 12.0% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 104 | 411 | $164,400 | $33,469 | 20.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 104 | 267 | $73,425 | $14,674 | 20.0% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 15 | 22 | $11,770 | $2,806 | 23.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 16 | 16 | $12,000 | $2,408 | 20.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 13 | 20 | $3,400 | $1,238 | 36.4% |
| 99238 | Hospital discharge day management, 30 minutes or less | Facility | 2021 | 12 | 15 | $2,700 | $940.80 | 34.8% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Facility | 2021 | 20 | 30 | $5,100 | $926.20 | 18.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 87 | 381 | $152,400 | $24,516 | 16.1% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 65 | 129 | $35,475 | $5,261 | 14.8% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 29 | 29 | $21,750 | $4,212 | 19.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 15 | 35 | $5,950 | $2,182 | 36.7% |
About Dr. Jorge Nieva, M.D
Dr. Jorge Nieva, M.D is a Hematology & Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1497717672.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Jorge Nieva, M.D has received a total of $59,255 in payments from pharmaceutical and medical device companies, with $10,383 received in 2024. These payments were reported across 132 transactions from 33 companies. The most common payment nature is "Consulting Fee" ($46,281).
As a Medicare-enrolled provider, Nieva has provided services to 1,013 Medicare beneficiaries, totaling 2,542 services with total Medicare billing of $182,754. Data is available for 4 years (2020–2023), covering 26 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Los Angeles, CA
- Active Since 04/04/2006
- Last Updated 11/27/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1497717672
Products in Payments
- ALUNBRIG (Drug) $7,901
- IMFINZI (Drug) $5,130
- Alecensa (Biological) $4,622
- TAGRISSO (Drug) $3,603
- TECENTRIQ (Biological) $3,553
- Tecentriq (Biological) $3,375
- Non-Covered Product (Drug) $2,581
- COSELA (Drug) $1,500
- Fyarro (Drug) $1,500
- GILOTRIF (Drug) $1,500
- Vitrakvi (Drug) $900.00
- Udenyca (Biological) $451.72
- ROZLYTREK (Biological) $178.58
- LIBTAYO (Biological) $153.53
- CYRAMZA (Drug) $138.78
- KRAZATI (Drug) $133.56
- Monarch Platform (Device) $123.33
- LORBRENA (Drug) $113.31
- KEYTRUDA (Biological) $105.73
- ALIMTA (Drug) $70.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Los Angeles
Dennis Slamon, Md, MD
Hematology & Oncology — Payments: $4.3M
Hematology & Oncology $4.3M
George Yaghmour
Hematology & Oncology — Payments: $1.6M
Hematology & Oncology $1.6M
Dr. Robert Vescio, M.d, M.D
Hematology & Oncology — Payments: $1.4M
Hematology & Oncology $1.4M
Dr. Kevin Kelly, M.d, M.D
Hematology & Oncology — Payments: $1.1M
Hematology & Oncology $1.1M
David Berz, Md, Phd, Mph, MD, PHD, MPH
Hematology & Oncology — Payments: $613,380
Hematology & Oncology $613,380
Raghuveer Ranganathan, M.d, M.D
Hematology & Oncology — Payments: $472,334
Hematology & Oncology $472,334